VBL Therapeutics has entered a long-term lease contract for a new stand-alone facility in Modiin, Israel that will house its local biologics manufacturing facility, as the company plans for potential commercialization of Phase III oncology candidate, VB-111.   The site allows for modular expansion of manufacturing capacity to supply demand following commercialization, while requiring limited capital resources in the immediate stage. The company projects that its current cash will support opera...